Tafenoquine at therapeutic concentrations does not prolong fridericia-corrected QT interval in healthy subjects

Tafenoquine is being developed for relapse prevention in Plasmodium vivax malaria. This Phase I, single-blind, randomized, placebo- and active-controlled parallel group study investigated whether tafenoquine at supratherapeutic and therapeutic concentrations prolonged cardiac repolarization in healt...

Descripción completa

Detalles Bibliográficos
Autores principales: Green, Justin A, Patel, Apurva K, Patel, Bela R, Hussaini, Azra, Harrell, Emma J, McDonald, Mirna J, Carter, Nick, Mohamed, Khadeeja, Duparc, Stephan, Miller, Ann K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Drug Safety
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283056/
https://www.ncbi.nlm.nih.gov/pubmed/24700490
http://dx.doi.org/10.1002/jcph.302

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283056/
https://www.ncbi.nlm.nih.gov/pubmed/24700490
http://dx.doi.org/10.1002/jcph.302

Ejemplares similares